ROLE AND EFFICACY OF SERUM CA-125 IN THE DIAGNOSIS OF MALIGNANCY IN ADNEXAL MASS WITH HISTOPATHOGICAL CORRELATION
Main Article Content
Keywords
Adnexal mass, CA 125, Histopathology
Abstract
To identify the efficacy of serum CA-125 levels in the diagnosis of malignancy in adnexal mass and its correlation with histo-pathological reports.
METHODS: This is hospital based observational study for a period of 1 year which included 133 patients of adnexal mass attending the OPD who required admission and operative intervention. Following surgery specimens were sent for histopathological examination and the reports were correlated with CA 125 levels.
RESULT: Out of 33 malignant tumors, 25 (75.75%) had serum CA125 >35 U/ml, whereas out of the 100 benign tumors , only 33 (33%) had serum CA125 >35 U/ml ; these benign mass mainly belonged to the epithelial cell tumor group and inflammatory tubo-ovarian mass. Out of the 33 malignant tumors, only 8 (24.24%) had serum CA125 <35 U/ml, these include endodermal sinus tumor , dysgerminoma, granulosa cell tumor and immature teratoma. The mean and median values for serum CA 125 in the subjects with malignant disease were 235.99 and 112.0 respectively, the corresponding values in the subjects with benign disease were 31.93 and 21.63 respectively. The association between was statistically significant at a p value of <0.001. Serum CA 125 had an area of 0.838, SE of 0.065 and Asymptomatic 95% CI of 0.711 to 0.964.
CONCLUSION: Serum CA 125 level is effective in differentiating between benign and malignant adnexal mass since it has CA-125 levels have good sensitivity and specificity, but it is increased in few benign condition also. Hence it can be used as biochemical marker in differentiating malignancy from benign tumors.
References
2. Ayhan A, Guven S, Guven ES, Kucukali T. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstetricia et Gynecologica Scandinavica. 2007 ;86(4):484-490. DOI: 10.1080/00016340701226138. PMID: 17486473.
3. Milojkovic, M., Hrgovic, Z., Hrgovic, I. et al. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis. Arch Gynecol Obstet 269, 176–180 (2004).
4. Hasholzner U, Baumgartner L, Stieber P, et al. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma. Anticancer Research. 1994 Nov-Dec;14(6B):2743-2746. PMID: 7532929.
5. Poncelet C, Fauvet R, Yazbeck C, Coutant C, Darai E. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study. European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2010 Nov;36(11):1066-1072. DOI: 10.1016/j.ejso.2010.07.004. PMID: 20817462.
6. Engelen MJ, de Bruijn HW, Hollema H, et al. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Gynecologic Oncology. 2000 Jul;78(1):16-20. DOI: 10.1006/gyno.2000.5811. PMID: 10873403.
7. Behnamfar F, Esmaeilian F, Adibi A, Rouholamin S. Comparison of Ultrasound and Tumor Marker CA125 in Diagnosis of Adnexal Mass Malignancies. Adv Biomed Res. 2022 Feb 28;11:18. doi: 10.4103/abr.abr_164_20. PMID: 35386543; PMCID: PMC8977613.
8. McDonald, John M. MD; Doran, Stacey BS; DeSimone, Christopher P. MD; Ueland, Fred R. MD; DePriest, Paul D. MD; Ware, Rachel A. MD; Saunders, Brook A. MD; Pavlik, Edward J. PhD; Goodrich, Scott MD; Kryscio, Richard J. PhD; van Nagell, John R. Jr MD. Predicting Risk of Malignancy in Adnexal Masses. Obstetrics & Gynecology 115(4):p 687-694, April 2010.
9. Oehler MK, Sütterlin M, Caffier H. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer. Anticancer Res. 1999 Jul-Aug;19(4A):2513-2518. PMID: 10470185.
10. Sehouli J, Akdogan Z, Heinze T, Könsgen D, Stengel D, Mustea A, Lichtenegger W. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. Anticancer Res. 2003 Mar-Apr;23(2A):1115-1118. PMID: 12820357.
11. Khoiwal K, Bahadur A, Kumari R, Bhattacharya N, Rao S, Chaturvedi J. Assessment of Diagnostic Value of Serum Ca-125 and Risk of Malignancy Index Scoring in the Evaluation of Adnexal Masses. J Midlife Health. 2019 Oct-Dec;10(4):192-196. doi: 10.4103/jmh.JMH_84_19. PMID: 31942155; PMCID: PMC6947724.
12. Rossi AC, Di Vagno G, Cormio G, et al. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer. Archives of Gynecology and Obstetrics. 2004 May;269(4):263-265. DOI: 10.1007/s00404-002-0404-6. PMID: 14745561.
13. Zeimet AG, Guadagni F, Marth C, et al. [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker]. Geburtshilfe und Frauenheilkunde. 1995 Apr;55(4):195-199. DOI: 10.1055/s-2007-1023300. PMID: 7789707.
14. Bozkurt M, Yumru AE, Aral I. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy. Eur J Gynaecol Oncol. 2013;34:540–4.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Sadhana bharati
Assistant professor , department of obstetrics and gynaecology, MRAMC Ambedkar nagar
Dr Shalini chauhan
Assistant professor ,department of obstetrics and gynaecology, ASMC, Auraiya
Dr Sachin Siddu
Assistant professor, department of obstetrics and gynaecology, MIMS Mandya
Dr Sunil kumar
Assistant professor, department of surgery, BKASMC Chandauli
